Document Detail

Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa.
MedLine Citation:
PMID:  20453629     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: We assessed risk factors for viremia and drug resistance among long-term recipients of antiretroviral therapy (ART) in South Africa.
METHODS: In 2008, we conducted a cross-sectional study among patients receiving ART for 12 months or more. Genotypic resistance testing was performed on individuals with a viral load higher than 400 RNA copies/ml. Multiple logistic regression analysis was used to assess associations.
RESULTS: Of 998 participants, 75% were women with a median age of 41 years. Most (64%) had been on treatment for more than 3 years. The prevalence of viremia was 14% (n = 139): 12% (102/883) on first-line [i.e. nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based regimen] and 33% (37/115) on second-line (i.e. protease inhibitor (PI)-based regimen) ART. Of viremic patients, 78% had drug resistance mutations. For NRTIs, NNRTIs and PIs, the prevalence of mutations was 64, 81 and 2%, respectively, among first-line failures and 29, 54 and 6%, respectively, among second-line failures. M184V/I, K103N and V106A/M were the most common mutations. Significant risk factors associated with viremia on first-line regimen included concurrent tuberculosis treatment [odds ratio (OR) 6.4, 95% confidence interval (CI) 2.2-18.8, P < 0.01] and a recent history of poor adherence (OR 2.7, 1.3-5.6, P = 0.01). Among second-line failures, attending a public clinic (OR 4.6, 95% CI 1.8-11.3, P < 0.01) and not having a refrigerator at home (OR 6.7, 95% CI 1.2-37.5, P = 0.03) were risk factors for virological failure.
CONCLUSION: Risk factors for viral failure were line regimen dependent. Second-line ART recipients had a higher rate of viremia, albeit with infrequent PI drug resistance mutations. Measures to maintain effective virologic suppression should include increased adherence counseling, attention to concomitant tuberculosis treatment and heat-stable formulations of second-line ART regimens.
Ziad El-Khatib; Anna Mia Ekstrom; Johanna Ledwaba; Lerato Mohapi; Fatima Laher; Alan Karstaedt; Salome Charalambous; Max Petzold; David Katzenstein; Lynn Morris
Related Documents :
25219139 - The -323p0/p10 factor vii gene polymorphism and the risk of recurrent miscarriage.
20648009 - Combined effect of socioeconomic status, viral hepatitis, and lifestyles on hepatocellu...
14644799 - Satellite and mobile wireless transmission of focused assessment with sonography in tra...
25322899 - Gender-specific genetic associations of polymorphisms in ace, akr1c2, fto and mmp2 with...
20595659 - Differential effects of chromosome 9p21 variation on subphenotypes of intracranial aneu...
25488799 - Synovitis in knee osteoarthritis: a precursor of disease?
18991899 - Comparative environmental health assessments.
1504269 - Update on oral contraceptive pills and postcoital contraception.
23066159 - Proximity of first sexual intercourse to menarche and risk of high-grade cervical disease.
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  AIDS (London, England)     Volume:  24     ISSN:  1473-5571     ISO Abbreviation:  AIDS     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-06-30     Completed Date:  2010-08-19     Revised Date:  2014-09-24    
Medline Journal Info:
Nlm Unique ID:  8710219     Medline TA:  AIDS     Country:  England    
Other Details:
Languages:  eng     Pagination:  1679-87     Citation Subset:  IM; X    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-HIV Agents / therapeutic use*
Antiretroviral Therapy, Highly Active / methods
Drug Resistance, Viral*
Epidemiologic Methods
HIV Infections / drug therapy*,  epidemiology,  virology
HIV-1 / drug effects*,  isolation & purification
Middle Aged
Patient Compliance
Socioeconomic Factors
South Africa / epidemiology
Treatment Failure
Viral Load
Viremia / drug therapy*,  epidemiology,  virology
Grant Support
2 U2R TW006878/TW/FIC NIH HHS; U2R TW006878/TW/FIC NIH HHS; U2R TW006878-01A1/TW/FIC NIH HHS
Reg. No./Substance:
0/Anti-HIV Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells throug...
Next Document:  Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined anti...